Novartis Ag (NVS) Short-Term Debt repayments (2019 - 2026)

Novartis Ag's Short-Term Debt repayments history runs 8 years deep, the most recent figure standing at -$73.0 million for Q1 2026.

• In Q1 2026, Short-Term Debt repayments fell 5.8% year-over-year to -$73.0 million; the TTM figure through Mar 2026 stood at -$285.0 million (down 7.95% YoY), while the FY2025 annual figure was -$281.0 million, down 7.25% from the prior year.
• Short-Term Debt repayments came in at -$73.0 million for Q1 2026 at Novartis Ag, roughly flat from -$73.0 million in the prior quarter.
• In the past five years, Short-Term Debt repayments ranged from a high of -$59.0 million in Q2 2024 to a low of -$77.0 million in Q1 2022.
• A 5-year average of -$67.8 million and a median of -$66.0 million in 2023 frame the typical range for Short-Term Debt repayments.
• Across the five-year window, Short-Term Debt repayments rose 20.0% in 2022 and slipped 14.06% in 2025, its largest moves.
• Novartis Ag's Short-Term Debt repayments stood at -$64.0 million in 2022, then changed by 0.0% to -$64.0 million in 2023, then fell by 12.5% to -$72.0 million in 2024, then fell by 1.39% to -$73.0 million in 2025, then changed by 0.0% to -$73.0 million in 2026.
• According to Business Quant data, Short-Term Debt repayments over the past three periods registered -$73.0 million, -$73.0 million, and -$73.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison